Roche signals beyond the news: 47+ signals from 5 sources
The latest Roche signal on this page is from Sep 29, 2026 (Patents): "Roche Diagnostics was granted a patent for mass-spectrometry reagents." The busiest sources: Glassdoor (15+), Website changes (15+) and Patents (12).
- Signals
- 47+
- Sources
- 5
- Last 90 days
- 45
- Latest
- Sep 29, 2026
Other signals · latest 10
Latest Roche signals by source
47+ signals for Roche across 5 sources.
Patents · Patent grant
Roche Diagnostics was granted a patent for mass-spectrometry reagents
In September 2026 Roche Diagnostics patented chemical reagents for identifying and measuring analyte molecules in laboratory mass-spectrometry workflows.
- Patent title
- Reagent for mass spectrometry
- Grant date
- Sep 29, 2026
- Inventors
- Robert Hahn, Dieter Heindl, Hans-Peter Josel, Uwe Kobold
Patents · Patent pace
Roche Sequencing Solutions, Inc.'s patent output is accelerating: 26 grants in the past year, 3 in the past 30 days.
Over the past year Roche Sequencing Solutions, Inc. received 26 US patent grants; the recent pace (7 in 90 days) is accelerating versus its trailing baseline.
- Grants, 12 months
- 26
- Grants, 90 days
- 7
- Grants, 30 days
- 3
- Pace
- Accelerating
Patents · Patent counsel
Roche Sequencing Solutions, Inc. uses Roche Sequencing Solutions, Inc. as outside IP counsel.
Roche Sequencing Solutions, Inc. is the attorney of record on Roche Sequencing Solutions, Inc.'s recent US patent work, including a grant in 2026-09.
- Law firm
- Roche Sequencing Solutions, Inc.
- Matter date
- Sep 29, 2026
Glassdoor · Consistent leadership complaints
Multiple reviews cite toxic leadership and disconnected management
Several employees describe a lack of leadership skills, political behavior, and a disconnect between senior management and the rest of the team, leading to exhaustion and unclear roles.
- Overall rating
- 4.2 of 5
- CEO approval
- 86%
- Reviews read
- 10
- Review window
- Aug 26, 2026 to Sep 5, 2026
Glassdoor · Growth opportunities
Employees report limited career advancement and unclear promotion paths
Multiple reviews indicate a lack of career growth, with low ratings for career opportunities and mentions of unclear promotion criteria and internal competition.
- Overall rating
- 4.2 of 5
- CEO approval
- 86%
- Reviews read
- 10
- Review window
- Aug 26, 2026 to Sep 5, 2026
Website changes · Product update
Roche replaced its Ukraine support hotline with a dedicated Roche.ua website for dedicated support hotline contacts and medical information.
Removed: “Roche has established a multilingual support hotline for patients and healthcare providers in or from Ukraine” and its phone, WhatsApp, email, and operating hours; added: “Ukraine Support Hotline & Contact Information Please visit” with a link to https://www.roche.ua/ for dedicated support hotline...
- Page
- /contact
Website changes · Website update
Roche substantially refreshed the contact page’s navigation and supporting imagery, including new visual assets for strategy, business, governance, ethical standards, pipeline, and privacy...
The page replaced the prior “Our strategy,” “Our business,” “Governance,” “Product Development Pipeline,” and “Privacy notice” links with new image-based sections and labels, while adding new 320px/256px assets.
- Page
- /contact
Web traffic · Traffic snapshot
roche.com received 1M monthly visits with traffic from 5 countries.
Emerging AI traffic at 1% (~13,551 visits). Top: chatgpt.com (81%), gemini.google.com (4%), claude.ai (4%), perplexity.ai (0%).
- Monthly visits
- 1,339,440
- Month over month
- +14.5%
- 3-month change
- +4.7%
- Global rank
- 36,411
Podcasts · Tech adoption
Analyse Podcast discusses Roche: tech adoption
"One of the best use cases we've found is coming from Roche. Roche is a big pharmaceutical company. One of the people working in their legal department, so in charge of patents, has taken a task to completely revamp how his team is operating with making decisions around patentability and..."
- Podcast
- Analyse Podcast
- Episode
- The Three Ingredients That Turn AI Into Value with Sophie Dionnet
- Speaker
- Sophie Dionnet
- Speaker role
- Counterparty
Web traffic · Sustained decline
roche.com shows sustained decline with 3 consecutive months of decreases, down 28% overall to 1M.
Emerging AI traffic at 1.3% (~15,241 visits). Top: chatgpt.com (92%), perplexity.ai (5%), gemini.google.com (3%), claude.ai (0%).
- Monthly visits
- 1,169,307
- Month over month
- -8.6%
- 3-month change
- -27.6%
- Global rank
- 40,032
Showing 10 of 47+ signals. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track Roche with the Signal API
One POST /v1/companies/enrich call with roche.com returns Roche signals from 14 more signal types (reddit-company, podcast-company, glassdoor-company and more), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{
"domain": "roche.com",
"signal_types": ["reddit-company","podcast-company","glassdoor-company",
"product-reviews","linkedin-post-company","twitter-company-posts",
"youtube-company","website-intelligence","patents-company",
"federal-contract-award","conference-speaker","hackernews",
"producthunt-launch","seo-traffic"],
"limit": 20
}'Same industry
Other signals at related companies
Questions about Roche other signals
What signals does Autobound track for Roche besides news and filings?
What are people saying about Roche online?
What do employees say about working at Roche?
Has Roche been granted patents recently?
Source. Reddit, podcasts, Glassdoor, product reviews, LinkedIn, X, YouTube, company websites, patents, federal contracts, conference talks, Hacker News, Product Hunt, web traffic and employee growth, from the Signal API.
Method. The latest 15 signals per source from the last 12 months. Posts that do not name the company, replies, repeats and unreadable rows are removed. Traffic and headcount keep their newest measure.
Data as of .